Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for vitreous hemorrhage in proliferative diabetic retinopathy
ACTRN12618000697280Phase 3Recruiting
- Sponsor
- Hospital Oftalmológico de Sorocaba
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of bevacizumab in diabetic retinopathy (DR) (2 arms), sponsored by Hospital Oftalmológico de Sorocaba. Primary endpoints: Absorption of vitreous hemorrhage enabling photocoagulation and Percentage of patients who did not need vitrectomy. Started May 2017; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on ACTRN12618000697280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000697280.